Does a Single Intravenous Injection of the 5HT3 Receptor Antagonist Ondansetron Have an Analgesic Effect in Neuropathic Pain? A Double-Blinded, Placebo-Controlled Cross-Over Study

Anesthesia and Analgesia

Volumn 97, Issue 5, 2003, Pages 1474-1478

  McCleane, Gary J ^a   Suzuki, Rie ^b   Dickenson, Anthony H ^b  

^a Rampark Pain Centre   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROKININ; NEUROKININ 1; ONDANSETRON; PLACEBO; SEROTONIN 3 ANTAGONIST; UNCLASSIFIED DRUG;

ADULT; ANALGESIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEADACHE; HUMAN; MALE; NEUROPATHIC PAIN; NOCICEPTIVE STIMULATION; PRIORITY JOURNAL; RASH; SIDE EFFECT; SINGLE DRUG DOSE; SPINAL CORD NERVE CELL; URTICARIA; VERTIGO;

EID: 0142150238     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ANE.0000085640.69855.51     Document Type: Article

References (24)

1. Yu XH, Zhang ET, Craig AD, et al. NK-1 receptor immunoreactivity in distinct morphological types of lamina I neurons of the primate spinal cord. J Neurosci 1999;19:3545-55.
2. Hunt S, Mantyh P. The molecular dynamics of pain control. Nature Reviews 2001;2:83-91.
3. Marshall G, Shehab S, Spike R, Todd A. Neurokinin-1 receptors on lumbar spinothalamic neurons in the rat. Neuroscience 1996;72:255-63.
4. Gauriau C, Bernard J. Pain pathways and parabrachial circuits in the rat. Exp Physiol 2002;87:251-8.
5. Suzuki R, Morcuende S, Weber M, et al. NK1 expressing neurones of the superficial dorsal horn control spinal excitability by activation of descending pathways. Nature Neuroscience 2002;5:1319-26.
6. Bernard J, Bester H, Besson J. Involvement of the spino-brachio-amygdaloid and hypothalamic pathways in the autonomic and affective emotional aspects of pain. Prog Brain Res 1996;107:243-55.
7. Bowker R, Westlund K, Sullivan M, et al. Descending serotonergic, peptidergic and cholinergic pathways from the raphe nuclei: a multiple transmitter complex. Brain Res 1983;288:33-48.
8. Cui M, Feng Y, McAdoo D, Willis W, Periaqueductal gray stimulation-induced inhibition of nociceptive dorsal horn neurons in rats is associated with the release of norepinephrine, serotonin and amino acids. J Pharmacol Exp Ther 1999;289:868-76.
9. Zeitz KP, Guy N, Malmberg AB, et al. The 5-HT3 subtype of serotonin receptor contributes to nociceptive processing via a novel subset of myelinated and unmyelinated nociceptors. J Neurosci 2002;22:1010-9.
10. Green G, Scarth J, Dickenson A. An excitatory role for 5-HT in spinal inflammatory nociceptive transmission; state-dependent actions via dorsal horn 5-HT3 receptors in the anaesthetized rat. Pain 2000;89:81-8.
11. Ali Z, Wu G, Kozlov A, Barasi S. The role of 5-HT3 in antinociceptive processing in the rat spinal cord: results from behavioural and electrophysiological studies. Neurocsi Lett 1996;208:203-7.
12. Tramer MR, Reynolds DJ, Stoner NS, et al. Efficacy of 5-HT3 receptor antagonists in radiotherapy-induced nausea and vomiting: a quantitative systematic review. Eur J Cancer 1998;34:1836-44.
13. Simpson KH, Murphy P, Colthup PV, Whelan P. Concentration of ondansetron in cerebrospinal fluid following oral dosing in volunteers. Psychopharmacology 1992;109:497-8.
14. Farber L, Stratz TH, Bruckle W, et al. Short-term treatment of primary fibromyalgia with the 5-HT3 receptor antagonist tropisetron: results of a randomized, double-blind, placebo-controlled multicenter trial in 418 patients. Int J Clin Pharmacol Res 2001;21:1-13.
15. Muller W, Stratz T. Results of the intravenous administration of tropisetron in fibromyalgia patients. Scand J Rheumatol 2000; Suppl 113:59-62.
16. Haus U, Varga B, Stratz T, et al. Oral treatment of fibromyalgia with tropisetron given over 28 days: influence on functional and vegetative symptoms, psychometric parameters and pain. Scand J Rheumatol 2000;Suppl 113:55-8.
17. Camilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Alimen Pharmacol Ther 1999;13:1149-59.
18. Watson ME, Lacey L, Kong S, et al. Alosetron improves quality of life in women with diarrhoea - predominant irritable bowel syndrome. Am J Gastroenetrol 2001;96:455-9.
19. Camilleri M, Chey WY, Mayer EA, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhoea - predominant irritable bowel syndrome. Arch Intern Med 2001;161:1733-40.
20. Friedel D, Thomas R, Fisher RS. Ischaemic colitis during treatment with alosetron. Gastroenterology 2001;120:557-60.
21. Lievre M. Alosetron for irritable bowel syndrome. Br Med J 2002;325:555-6.
22. Ye JH, Mui WC, Ren J, et al. Ondansetron exhibits the properties of a local anesthetic. Anesth Analg 1997;85:1116-21.
23. Reddy MS, Chen FG, Ng HP. Effect of ondansetron pretreatment on pain after rocuronium and propofol injection: a randomised, double-blind controlled comparison with lidocaine. Anaesthesia 2001;56:879-905.
24. Ambesh SP, Dubey PK, Sinha PK. Ondansetron pretreatment to alleviate pain on propofol injection: a randomized, controlled, double-blinded study. Anesth Analg 1999;98:197-9.